Substituted quinazolin-4-one derivatives

US9840498B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Zhenxing DU · 安丰镇, CN
• Samuel Hintermann · Basel, CH
• Konstanze Hurth · Rixheim, FR
• Sebastien Jacquier · Hégenheim, FR
• Hansjoerg Lehmann · Basel, CH
• Henrik Moebitz · Glückstadt, DE
• Nicolas Soldermann · Rixheim, FR
• Aleksandar Stojanovic · Allschwil, CH

Key dates

• Filing date: Jul 24, 2014
• Grant date: Dec 12, 2017
• Expiry date: Jul 24, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.